Einfach E-Mail-Adresse eintragen und auf "Abschicken" klicken - willkommen!
Johnson & Johnson: Angebot für LifeScan-Übernahme
Der US-Pharma- und Konsumgüterkonzern Johnson & Johnson (J&J) hat ein Angebot für die Übernahme von LifeScan, Inc. erhalten. Dieses Unternehmen stellt Überwachungsgeräte für Diabetes-Patienten her. Wir veröffentlichen die Mitteilung von J & J in englischer Sprache.
Johnson & Johnson Corp.: ISIN: / WKN: 853260
Die untenstehende Meldung ist eine Original-Meldung der Unternehmen. Sie ist nicht von der ECOreporter.de-Redaktion bearbeitet. Die presserechtliche Verantwortlichkeit liegt bei dem meldenden Unternehmen.
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J. -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan, Inc. is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion.
"LifeScan's OneTouch® blood glucose monitoring products play an important role in the lives of millions of patients living with diabetes, and following a thorough review of all strategic options, we feel confident that the business would have a promising future with Platinum Equity," said Ashley McEvoy, Company Group Chairman, Consumer Medical Devices, Johnson & Johnson. "This initiative is part of our ongoing, disciplined approach to portfolio management to focus on our most promising opportunities to help patients and drive growth."
The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals, and Consumer businesses. These include important leadership and innovation in areas such as bariatric surgery and through medicines such as INVOKANA® (canagliflozin) and INVOKAMET® (canagliflozin/metformin HCl).
The acceptance period for the offer will end on June 15, 2018, unless extended, and during that time, consultations with relevant works councils are planned. If the offer is accepted, the transaction would be expected to close by the end of 2018, subject to the satisfaction of customary closing conditions. This transaction was contemplated in the Company's guidance provided on January 23, 2018.
About LifeScan, Inc.
LifeScan, Inc. is a world leader in blood glucose monitoring. In the US, LifeScan, Inc. is the leading maker of blood glucose monitoring systems and its OneTouch® brand products are recommended by more endocrinologists and primary care physicians than any other brand1. Globally, more than 20 million people depend on OneTouch® brand products for simple testing and accurate results to help them manage their diabetes. For more information visit: www.OneTouch.com.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.